Rationale: Post-myocardial infarction ventricular remodeling is associated with the expression of a variety of factors including S100B that can potentially modulate myocyte apoptosis. Objective: This study was undertaken to investigate the expression and function of S100B and its receptor, the receptor for advanced glycation end products (RAGE) in both postinfarction myocardium and in a rat neonatal myocyte culture model. Methods and Results: In a rat model of myocardial infarction following coronary artery ligation, we demonstrate in periinfarct myocytes, upregulation of RAGE, induction of S100B, and release into plasma with consequent myocyte apoptosis. Using a coimmunoprecipitation strategy, we demonstrate a direct interaction between S100B and RAGE. In rat neonatal cardiac myocyte cultures, S100B at concentrations >50 nmol/L induced myocyte apoptosis, as evidenced by increased terminal DNA fragmentation, TUNEL, cytochrome c release from mitochondria to cytoplasm, phosphorylation of extracellular signal-regulated kinase (ERK)1/2 and p53, increased expression and activity of proapoptotic caspase-3, and decreased expression of antiapoptotic Bcl-2. Transfection of a full-length cDNA of RAGE or a dominant-negative mutant of RAGE resulted in increased or attenuated S100B-induced myocyte apoptosis, respectively. Inhibition of ERK1/2 by U0126/PD-98059 or overexpression of a dominant negative p53 comparably inhibited S100B-induced myocyte apoptosis. Conclusions: These results suggest that interaction of RAGE and its ligand S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53 signaling. This receptor-mediated mechanism is uniquely amenable to therapeutic intervention. (Circ Res. 2010;106:93-101.)
T he structural and functional consequences of myocardial infarction (MI) relate to alterations in left ventricular (LV) geometry called post-MI ventricular remodeling. 1 This involves scar formation, ventricular dilation, hypertrophy of noninfarcted myocardium, and myocyte necrosis and apoptosis. Varied stimuli induce myocyte apoptosis, including neurohumoral factors, oxidants, cytokines, and potentially S100B. [2] [3] [4] S100B, a 20-kDa EF-hand Ca 2ϩ -binding dimer, is a member of a multi-genic family exhibiting tissue-specific expression, implicated in the regulation of a number of intracellular activities by interacting with effector proteins. 5 We have shown that S100B is induced in periinfarct myocytes after MI in human subjects and experimental rodent models. In transgenic and knockout mice, S100B is a negative regulator of myocyte hypertrophy, inhibits fetal gene expression, controls complex ventricular remodeling, and induces myocyte apoptosis following myocardial infarction. 4,6 -8 S100B is also released from cells and interacts in a paracrine (eg, microglia) or autocrine (eg, astrocytes) manner with trophic or apoptotic consequences depending on concentration. 5 In brain, S100B is released by astrocytes and at nanomolar concentrations stimulates neurite outgrowth and survival, whereas at micromolar concentrations, it causes astrocyte and neuronal apoptosis, in part through interaction with RAGE (receptor for advanced glycation end products). 5 RAGE is a multiligand receptor of the immunoglobulin superfamily, that interacts with distinct families of ligands, mediating diverse functions in a broad array of cell types including cellular migration, proliferation, survival and apoptosis. 5, 9 RAGE is expressed at low levels in most tissues and is upregulated at sites of pathology. 9 Intracellular mechanisms activated by RAGE interaction with ligands include the mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK)1/2, p38, c-Jun NH 2 -terminal kinase (JNK), and transcription factor nuclear factor B. 5, 9 In neonatal mouse cultures, exogenously administered S100B induces apoptosis in a dose-dependent manner, begin-ning at 100 nmol/L, a local or regional concentration that may be achieved in periinfarct myocardium. 4 Relevant to postinfarction, injured ischemic heart releases S100B. 10 Furthermore, in ischemic myocardium the expression of RAGE is upregulated. 11 These observations suggest that S100B may regulate apoptosis in post-MI myocardium by an extracellular mechanism following cellular release from damaged myocytes and interaction with RAGE. Alternatively, S100B may induce apoptosis in a RAGE-independent manner by interacting with an unidentified receptor as reported in myoblast cell lines. 12 In the present study, we aimed to: (1) demonstrate a possible direct interaction between RAGE and S100B in postinfarct myocardium; (2) determine whether RAGE is responsible for S100B-induced cardiac myocyte apoptosis; and (3) identify signaling mechanisms activated on RAGE ligation. Our results indicate that following experimental myocardial infarction, RAGE is upregulated and colocalizes with S100B in periinfarct myocardium. In isolated myocytes, RAGE ligation by S100B induced myocyte apoptosis by activation of ERK1/2 signaling and p53.
Methods

Left Coronary Artery Ligation
Left anterior descending (LAD) coronary artery ligation was performed on 8-week-old Sprague-Dawley rats as previously described. 4, 13 On day 4, echocardiographic imaging (Sonos 5500 echocardiographic system, Philips Ultrasound, Bothell, Wash) was performed as previously described. 14 On days 7, 21, and 35 after LAD ligation, following the measurement of LV pressures, blood was sampled and mice were euthanized to harvest cardiac tissue for RNA and protein isolation and fixation. All animal experiments conformed to protocols approved by St. Michael's Hospital Animal Care Committee.
Cell Culture and Transfection
The expression plasmids used included: human full-length RAGE pcDNARAGE, the cytoplasmic deletion mutant (⌬367 to 404)RAGE (described previously 15 ) , and the mutant form of the p53
His175 gene acting as a dominant negative 16 from S. Benchimol. Low-density (Ϸ150 cells/mm 2 ) neonatal rat cardiac myocytes cultures consisting of Ͻ5% non myocytes were isolated as previously described. 13 Transfection was carried out with FuGENE 6 reagent according to the instructions of the manufacturer (Roche, Indianapolis, Ind) using specific quantities of the following plasmids: RAGE, ⌬RAGE, dominant negative p53 (1 g).
Statistical Analysis
Treated/control ratios were tested for deviation from unity by calculation of confidence limits. Mean values were compared by one-way analysis of variance followed by Dunnett's test when appropriate, and by Student's t test where appropriate. Probability values of PϽ0.05 were accepted as statistically significant.
Results
Myocardial Infarction
In rat, proximal LAD ligation creates a large transmural infarction. 13 Infarct size was measured after 4 days by echocardiography because at this time point, scar formation was incomplete and the infarction area could be distinguished by wall motion (infarct size, 41Ϯ6% of total LV circumference at the papillary muscle level). After 35 days, scar formation was complete and the infarct zone thinned markedly (infarct size 51Ϯ9% of LV circumference, nϭ6). Compared to sham animals, the infarcted group after 7, 21, and 35 days had no significant differences in mean arterial pressure or (Ϯ)dP/dt, only increases in LV end diastolic pressure and myocardial hypertrophy (Online Table I , available in the Online Data Supplement at http://circres.ahajournals.org). The hemodynamic profile is indicative of the compensatory phase postinfarction. 17 Periinfarct LV myocardium at any given time point displayed genomic DNA fragmentation (35 days after MI; Figure 1A ) and a progressive increase in caspase-3 activity ( Figure 1B) . Similarly, a significantly (PϽ0.05) greater number of apoptotic cells were detected in periinfarct LV myocardium by TUNEL staining at 35 days compared to either 7 or 21 days ( Figure 1C ).
Induction of S100B and RAGE After Myocardial Infarction
Plasma S100B levels were increased in infarcted rats compared to sham-operated controls ( Figure 1D ), with highest levels at 35 days after MI. We measured 10 pmol/L S100B dimer in plasma, which is in line with levels released by ischemic rat heart. 10 To verify that cardiomyocytes release S100B, we measured S100B levels in medium from cultured cardiomyocytes following 24 hours of hypoxia. Under hypoxic conditions, S100B levels were significantly (PϽ0.05) increased in cultured medium (Figure 1E ). At 7, 21, and 35 days after MI S100A1, S100B and RAGE mRNA levels were determined by real-time RT-PCR. At a given time point, S100A1 was downregulated, S100B was induced, and RAGE was upregulated in rat periinfarct LV myocardium compared with shamtreated LV myocardium (Figure 2A) . We also performed Western blot analysis on LV tissue lysates. Densitometry ratios show that S100A1 protein levels were decreased and S100B and RAGE levels were increased in periinfarct LV myocardium ( Figure 2B ).
Colocalization of S100B and RAGE in Periinfarct Myocardium
Double labeling with fluorochrome-labeled secondary antibodies and confocal microscopy demonstrated diffuse S100B and RAGE fluorescence of myocardial cells in surviving periinfarct LV myocardium 35 days after MI ( Figure 3A) . Myocyte expression of S100B and RAGE was confirmed by colabeling with myocyte specific marker MF-20 as seen in the merged images ( Figure 3A , i through ii). Merged color images demonstrate a similar distribution S100B and RAGE ( Figure 3A , iii). A coimmunoprecipitation strategy followed by Western blot analysis demonstrated heterodimerization of S100B and RAGE ( Figure 3B ) and S100A1 and RAGE (Online Figure I ) in periinfarct LV myocardium. Specificity was confirmed as no S100B, S100A1, or RAGE was detected in immune complexes formed with normal rabbit (S100B, S100A1) or goat (RAGE) serum, respectively (data not shown). We also confirmed RAGE expression in isolated cardiomyocytes ( Figure 3C ). The RAGE (C-20) antibody used above for Western and immunofluorescence detection of RAGE shows diffuse membrane and cellular staining of cardiomyocytes ( Figure 3C , i). RAGE (A11) antibody raised against a truncated extracellular domain of RAGE shows predominantly membrane staining of cardiomyocytes, as identified by costaining with MF-20 ( Figure 3C , ii and iii). Western blot analysis using RAGE (C-20) demonstrates low level RAGE protein in untreated/vector transfected cardiomyocytes and enhanced levels in myocytes transfected with human RAGE expression vector ( Figure 3D ). Transfection with ⌬CytoRAGE revealed 2 bands: a higher and lower band indicating full-length RAGE and truncated ⌬CytoRAGE, respectively ( Figure 3D ). Densitometry measurements (RAGE/␤Actin) show full-length RAGE expression with ⌬CytoRAGE (cytoplasmic deletion mutant of RAGE) transfection (9.98Ϯ1.18) was not significantly (PϾ0.05) different from transfection of vector alone (8.81Ϯ1.06) (nϭ3). 
RAGE Ligation by S100B Induces Myocyte Apoptosis
Treatment of cardiomyocytes for 48 hours with increasing doses of S100B caused a dose dependent increase in DNA fragmentation as visualized by DNA laddering ( Figure 4A ) and TUNEL staining ( Figure 4B ). A progressive increase in cardiomyocyte apoptosis was first observed at 0.05 mol/L of S100B relative to vehicle treatment ( Figure 4C ). To determine whether RAGE was the receptor responsible for S100B-induced apoptosis, cardiomyocytes were transfected with either a human RAGE or ⌬CytoRAGE expression vector. Transfection of either human RAGE or ⌬CytoRAGE resulted in an increase in cardiomyocyte RAGE protein ( Figure 3D ). Basal cardiomyocyte apoptosis expressed as per cent apoptotic nuclei was unaffected by any of the expression plasmids. With RAGE overexpression, S100B-induced apoptosis was significantly increased. In contrast, ⌬Cy-toRAGE inhibited S100B-induced apoptosis, suggesting RAGE dependence ( Figure 4D ).
RAGE Ligation by S100B Upregulates Capase-3, Downregulates Bcl-2 Expression, and Increases Caspase-3 Activity S100B induced an increase in cytochrome c release from mitochondria to cytoplasm that was potentiated with RAGE overexpression and inhibited in cardiomyocytes overexpressing ⌬CytoRAGE ( Figure 5A ). We next determined whether RAGE activation can regulate the expression of proapoptotic caspase-3 and antiapoptotic Bcl-2. Basal caspase-3 and Bcl-2 expression was unaffected by any transfected plasmid. S100B upregulated caspase-3, and downregulated Bcl-2, relative to vehicle treat- ment ( Figure 5B ). In cardiomyocytes expressing full-length RAGE, S100B further augmented caspase-3 and further attenuated Bcl-2, whereas ⌬CytoRAGE transfection had the opposite effects ( Figure 5B ). Similarly, with RAGE and ⌬CytoRAGE transfection, S100B induction of caspase-3 activity was augmented and attenuated, respectively ( Figure 5C ).
RAGE Ligation by S100B Activates the MAPK Cascade and p53
RAGE ligation by S100B activates the MAPK cascade. 18 -20 S100B increased the phosphorylation of JNK and p38 independent of RAGE ( Figure 6 ). Whereas, S100B increased ERK1/2 phosphorylation, a response potentiated with RAGE and inhibited by ⌬CytoRAGE overexpression ( Figure 7A ). S100B had no effect on the phosphorylation of Stat-3 or Janus kinase-2 phosphorylation (Online Figure II) . p53 is activated in response to varied stimuli and can induce apoptosis through activation of death-promoting gene targets. 21 S100B increased the phosphorylation of p53, a response potentiated in cardiomyocytes overexpressing RAGE and inhibited by ⌬CytoRAGE ( Figure 7A ). Demonstrating a functional role for p53 in RAGE overexpressing myocytes, dominant negative p53 inhibited S100B-induced myocyte apoptosis ( Figure 7B ).
Blockade of ERK1/2 and p53 Signaling Inhibits S100B-Induced, RAGE-Mediated Apoptosis
MAPK/ERK (MEK) activity has been shown to contribute to phosphorylation of p53 on serine residue 15 and the induction of p53-dependent apoptosis. 22 Pretreatment of cardiomyocytes with the MEK inhibitors U0126 or PD-98059 blocked S100B-induced phosphorylation of ERK1/2 and p53 with no effect on total ERK1/2 or p53 protein levels ( Figure 8A ). In addition, in myocytes overexpressing RAGE, pretreatment with either U0126 or PD-98059 inhibited S100B-induced apoptosis ( Figure 8B ). Pretreatment with the protein kinase A inhibitor KT-5720 had no effect on S100B-induced apoptosis ( Figure 8B ). Interestingly, pretreatment with the JNK inhibitor I, (L)-form cell permeable peptide (10 mol/L), and the p38 inhibitor PD169316 (10 mol/L) (Online Figure III) and cell transfection with small interfering RNAs targeting JNK1/2 and p38 (Online Figure IV ) had no effect on S100B-induced apoptosis. Coimmunoprecipitation demonstrated heterodimerization of ERK1/2 and p53 in response to S100B in RAGE overexpressing cardiomyocytes ( Figure 8C ). These data suggest that RAGE ligation by S100B activates 
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MEK signaling sensitizing myocytes to undergo p53-dependent apoptosis.
Discussion
We used a rat model of myocardial infarction provoked by LAD ligation to show that apoptosis and increased Caspase-3 activity, in periinfarct regions at 7, 21, and 35 days after LAD ligation is associated with induction of S100B, as previously described, 7,13 upregulation of RAGE, and release of S100B into plasma. Increase in caspase-3 activity late after MI has been observed in some, [23] [24] but not all, 25 previous experimental studies. The continued rise in S100B plasma levels in the absence of a further increase in tissue expression level may be attributable, in part, to release from damaged myocytes as cultured cardiomyocytes release S100B in response to hypoxic stimulus in keeping with recent observations of S100B release by isolated ischemic rat heart. 10 Because S100B expression is also increased in endothelial and vascular smooth muscle cells following ischemic injury, 26 -27 it is possible that these cell types present in the periinfarct region may also contribute to S100B release. Our data demonstrate that LAD occlusion itself induced S100B, thus underscoring a specific mechanism, non-AGE-dependent, by which ischemic injury may activate RAGE. Consistent with S100B as a ligand of RAGE, confocal microscopy and coimmunoprecipi- Figure 7 . RAGE ligation by S100B increases phosphorylation of ERK1/2 and p53. Rat myocytes were transfected with human wild-type RAGE or dominant negative RAGE (⌬ Cyto RAGE) or cotransfected with RAGE and dominant negative p53 and treated for 48 hours with S100B (1 mol/L) or vehicle. A, Phosphorylated and total ERK1/2 and p53 are shown in this representative Western blot. Bars are meansϩSEM of densitometry ratios (phosphorylated protein/total protein). *PϽ0.05 (nϭ3). B, Dominant negative p53 inhibits S100B-induced RAGE mediated myocyte apoptosis. Rat myocytes were cotransfected with RAGE and dominant negative p53 (⌬p53) and treated for 48 hours with S100B (0.05 to 1 mol/L) or vehicle. Bars are meansϩSEM of TUNEL-positive/total myocyte nuclei per highpower field. *PϽ0.05 vs vehicle/vector (nϭ6). tation demonstrate similar cellular distribution and association of S100B and RAGE in periinfarct ventricular myocardium. In neurons, extracellular S100B exerts a dual concentration-dependent effect: prosurvival effects on neurons and neurite outgrowth at low nanomolar doses and apoptotic effects at micromolar doses. 15 We demonstrate in cardiomyocytes exogenous S100B results in cytochrome c release, increased expression and activity of caspase-3, decreased expression of Bcl-2, and the induction of cardiomyocyte apoptosis in a dose dependent manner beginning at 0.05 mol/L. However, these findings raise the question of the functional relevance of S100B measured in plasma which are approximately 1000-fold less than the dose required to induce apoptosis. Local or regional concentrations of S100B may be much higher in periinfarct myocardium. 4 Local accumulation of S100B from release from damaged myocytes with consequent leakage of endogenous S100B may provide nanomolar concentrations of this protein at the vicinity of myocytes where it can influence apoptosis. Interestingly, S100B caused myoblast apoptosis at concentrations greater then 5 nmol/L. 12 We cannot exclude that intracellular S100B may modulate apoptotic responses of postinfarct myocytes. Although there may be susceptibility differences between neonatal and adult myocytes, we documented the presence of apoptosis in the periinfarct region at 7, 21, and 35 days after LAD ligation, in regions demonstrating S100B and RAGE expression, but not in the hearts of sham-operated controls. Necrosis was not measured, and we were unable to demonstrate a correlation between MI size and S100B levels, given the limited range of MI sizes in the study. In addition to S100B, diverse factors including the alternate RAGE ligand, high-mobility group box-1, 28 prostaglandins, 29 and tumor necrosis factor ␣ 30 are upregulated after MI and induce apoptosis.
Interaction of S100B with RAGE has been implicated in both dose-dependent and cell-specific neurotrophic and neurotoxic effects of S100B. 15, 31 Interaction of S100B at micromolar concentrations with RAGE has been implicated in both apoptosis 15 and proliferation 31 by specifically binding RAGE receptor domains V and C1. S100B may also induce apoptosis in a RAGE-independent manner by interacting with an unidentified receptor, as has been reported in myoblast cell lines, 12 or by increasing conductance in L-type Ca 2ϩ channels, as has been reported in PC12 cells. 32 In this study, we report that S100B-induced cardiomyocyte apoptosis is dependent on RAGE ligation because transfection of a RAGE expression vector potentiated, and a dominant negative cytoplasmic deletion mutant of RAGE inhibited, S100B-induced myocyte apoptosis as reported in N18 neuroblastoma cells with micromolar S100B concentrations. 15 Furthermore, S100B in the presence of forced RAGE expression increased the expression and activity of caspase-3 and attenuated the expression of Bcl-2, whereas dominant negative RAGE inhibited these S100B-induced responses to RAGE ligation. Interestingly, Bcl-2 expression levels have been shown to regulate cell sensitivity to S100B-induced apoptosis. 33 The above data indicate that persistent RAGE stimulation by S100B beginning at 0.05 mol/L activate the proapoptotic caspase cascade resulting in cardiomyocyte apoptosis.
RAGE ligation by S100B has been shown to induce an oxidant-stress dependent activation of ERK1/2, p38, and JNK MAP kinase pathways. 12, 15, 31 We demonstrate S100B increases the phosphorylation of JNK and p38 independent of RAGE signaling, whereas RAGE signaling by S100B results in persistent activation of the MEK-ERK1/2 pathway. The activation of ERK1/2 by S100B was profound and prolonged, unlike many growth factors, which show a rapid and transient increase in ERK1/2 phosphorylation. 34 Whereas activation of JNK and p38 pathways have been linked to cell stress and induction of apoptosis, 35 ERK1/2 has been linked to prosurvival pathways. 36 However, activation of ERK can contribute to cell death in diverse cultured cells. [37] [38] Inhibition of MEK-1/2 afforded some degree of protection against neuronal cell apoptosis induced by focal cerebral ischemia in rats. 39 We demonstrate that inhibiting JNK or p38 suppressed S100B-induced JNK and p38 phosphorylation. However, JNK inhibition with either the (L)-form cell permeable peptide and p38 inhibition with the classic blocker PD169316 or using small interfering RNAs to JNK and p38 had no effect on S100B-induced myocyte apoptosis. However, blockade of MEK activity suppressed S100B-induced, RAGE-mediated ERK1/2 phosphorylation and cardiomyocyte apoptosis as previously shown in neuroblastoma cells. 15 The ability of RAGE to activate ERKs may involve p21(ras) 18 or a direct interaction with ERK. 40 Activation of p53 can induce apoptosis through deathpromoting gene targets. 21 RAGE ligation by S100B increases the phosphorylation of p53 and overexpression of dominant negative p53 inhibits S100B-induced myocyte apoptosis suggesting a direct role of p53. Our study provides the first demonstration of p53 activation by the interaction of S100B and RAGE. Interestingly, intracellular S100B can activate p53 by contributing to nuclear accumulation 41 or decrease p53 transcriptional activity by disrupting tetramerization. 42 Several reports have suggested that ERK contributes to p53 activation by phosphorylation of p53 on serine 15. 22, 43 Phosphorylation of p53 at serine 15 by ERK leads to reduced binding to its negative regulator, oncoprotein murine double minute 2 (MDM2) 44 and increased binding to p300 coactivator protein. 45 We demonstrate that MEK inhibition not only suppressed S100B/RAGE activation of ERK1/2 phosphorylation but also phosphorylation of p53 at serine 15, suggesting that this phosphorylation contributes to p53 activation. Moreover, the expression of serine 15-phosphorylated p53 was associated with S100B/RAGE-induced myocyte apoptosis as it was decreased in MEK-inhibitor-treated myocytes. Using a coimmunoprecipitation strategy, we demonstrate an association of phospho-ERK1/2 and phospho-p53. Consistent with our observations, others report a p53-dependent apoptotic response associated with MEK MAPK activity and phosphorylation of p53 at serine 15. 20, 46 Our data suggests that RAGE activation by S100B increases MEK MAPK kinase signaling, p53 phosphorylation at serine 15, and p53-dependent myocyte apoptosis. Interestingly, whereas our data suggest a positive effect of MEK signaling on p53, a recent report demonstrates that JNK can act as a negative regulator of p53, 47 in keeping with our observed lack of response of JNK signaling on S100B-induced apoptosis. S100B effects on myocyte apoptosis stand in contrast to S100A1, the most abundant S100 protein expressed in cardiac muscle under basal conditions. 5 S100A1 exhibits increased expression in compensated hypertrophy, decreased expression in human cardiomyopathy, and downregulation following experimental myocardial infarction. 48 -49 Like our proposed mechanism for S100B release, S100A1 is released extracellularly in myocardial injury, and can bind RAGE (Online Figure I) . Unlike S100B, extracellular S100A1 inhibits apoptosis independent of RAGE 50 or by RAGE signaling by interacting with a different extracellular domain of RAGE as has been shown with other RAGE ligands. 31 Thus, S100 proteins may differentially regulate myocardial structure and function. Given the capacity of S100A1 and S100B to heterodimerize, phenotypic consequences may depend on the availability and stoichiometry of S100A1 and S100B homodimers and heterodimers.
In the present study, as in other studies, 51 a rat neonatal myocyte culture model has been used to address mechanisms involved in MI-induced apoptosis. One of the drawbacks of using adult rat cardiomyocytes in culture is the transition from elongated rod shape to polygonal spreading cells with numerous extensions, accompanied by dedifferentiation and redifferentiation processes. 52 However, when data from this study are applied to the in vivo setting, several points should be taken into account. First, because myocardial development is not complete at birth, differences may exist between neonatal and adult cardiomyocytes. Second, the biological properties of disassociated myocytes in culture and myocytes in the organized heart in vivo may differ. Third, as our data show, the concentration of S100B necessary to induce apoptosis is much higher than the concentration of S100B in rat plasma after MI.
In conclusion, we have shown that extracellular S100B, by interacting with RAGE at concentrations that may be achieved in periinfarct myocardium, induces cardiac myocyte apoptosis by a mechanism involving ERK1/2-dependent activation of p53. As we have demonstrated previously, absence of S100B in null mice is associated with structural and functional differences, as well as survival advantages; therefore, the S100B-RAGE signaling cascade is an attractive target for therapeutic intervention. 
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